NEW CASTLE, DE — BioTek reMEDys is urging expanded, year-round awareness and education surrounding rare autoinflammatory diseases—conditions that arise when the body’s immune system mistakenly attacks healthy tissues, leading to chronic inflammation and severe complications.
The company’s initiative builds on last August’s International Autoinflammatory Awareness Month, reinforcing its commitment to improving understanding of these complex disorders among patients, caregivers, and healthcare professionals.
Autoinflammatory diseases are caused by genetic mutations that disrupt normal immune responses, triggering repeated episodes of inflammation that can produce fever, rash, and joint swelling. Left untreated, they may lead to amyloidosis, a dangerous buildup of protein in vital organs. Because of their rarity and overlapping symptoms with other autoimmune conditions, they are often misdiagnosed or overlooked.
“Auto-inflammatory conditions and rare disease at large present such a tremendous challenge for patients, their families, caregivers, and healthcare providers,” said Andrew Babb, PharmD, CSP, IgCP, chief pharmacy officer at BioTek reMEDys. “Information, support, and guidance can be scarce, which only exacerbates the stress these patients feel. At BioTek reMEDys, we are committed to fostering awareness and will continue to advocate for the Rare Disease Community at a local and national level.”
Babb was recently appointed to Delaware’s inaugural Rare Disease Advisory Council (RDAC), established by Senate Bill 55 of the 152nd General Assembly. The council, housed within the Office of the Lieutenant Governor, serves as a multidisciplinary body advising state leaders, healthcare providers, and researchers on rare disease policy and resource development.
Chai Gadde, CEO and founder of BioTek reMEDys, emphasized the importance of education in improving diagnosis and treatment outcomes. “Because many autoimmune conditions are statistically rare, they can often be misdiagnosed,” Gadde said. “As an infusion therapy provider focused on the highly specific needs of patients living with rare conditions, we hope to help shine a light on the importance of education about these conditions.”
Treatments for autoinflammatory diseases typically focus on reducing inflammation or suppressing immune activity. By concentrating on narrowly defined disease states, BioTek reMEDys says it can ensure patients receive precise dosing, personalized therapies, and continuous care support.
The company’s ongoing advocacy reflects a growing push within the healthcare community to recognize rare diseases as a critical public health issue—one requiring stronger awareness, collaboration, and sustained investment in research and patient support.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.